الفهرس 
Non-Alcoholic Fatty Liver Disease (Nafld)Only 14 pages are availabe for public view
 |  | from | 253 |  |  |
| | | from | 253 | | |
Abstract
Introduction : Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. The long-term natural history of HCV infection is highly variable. The hepatic injury can range from minimal histological changes to extensive fibrosis and cirrhosis with or without hepatocellular carcinoma (HCC). There are approximately 71 million chronically infected individuals worldwide. Aim of the work: The aim of the study is to evaluate the role of serum Chemerin as a biomarker in patients with chronic hepatitis C virus with and without Non Alcoholic Fatty Liver Disease. Patients and methods: Type of study: A case control study. Study setting: outpatient clinics and inpatient wards at King Fahd hospital, Medina, Saudi Arabia & outpatient clinics at Ain Shams university hospitals, Egypt. Study Period: 6 months. Study Population: The study was conducted on normal populations, chronic HCV patients with NAFLD, and chronic HCV patients without NAFLD. Results: Atotal of 32 subjects with chronic HCV patients (16 without NAFLD, 16 with NAFLD), their ages range from 47to 60 years (18 males (56.2%)and 14 females (43.8%) and 16 normal subjects as control group, their ages range from 47 to 60 years, 9 males(56.2 %) and 7 females (43.8%). So more of the studied cases are mainly among males. Discussion: NAFLD is subdivided into nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). In NAFL, hepatic steatosis is present without evidence of significant inflammation, whereas in NASH, hepatic steatosis is associated with hepatic inflammation that may be histologically indistinguishable from alcoholic steatohepatitis Conclusion: The results obtained in the current study demonstrate that the serum chemerin level increased in parallel with the worsening liver functional reserves in CHC patients and serum chemerin level incrased in patients with CHC associated with NAFLD. It could be concluded that chemerin may be considered as additional tools for assessment of prognosis of CHC and monitoring the virally derived metabolic abnormality.